GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Cyclically Adjusted Revenue per Share

NeuroMetrix (NeuroMetrix) Cyclically Adjusted Revenue per Share : $862.46 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NeuroMetrix's adjusted revenue per share for the three months ended in Dec. 2023 was $1.141. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $862.46 for the trailing ten years ended in Dec. 2023.

During the past 12 months, NeuroMetrix's average Cyclically Adjusted Revenue Growth Rate was -39.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -50.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -52.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -44.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of NeuroMetrix was -12.40% per year. The lowest was -58.50% per year. And the median was -47.10% per year.

As of today (2024-04-27), NeuroMetrix's current stock price is $4.44. NeuroMetrix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $862.46. NeuroMetrix's Cyclically Adjusted PS Ratio of today is 0.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NeuroMetrix was 0.04. The lowest was 0.01. And the median was 0.02.


NeuroMetrix Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for NeuroMetrix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Cyclically Adjusted Revenue per Share Chart

NeuroMetrix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13,355.60 6,905.56 2,247.88 1,415.96 862.46

NeuroMetrix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,415.96 1,258.52 1,120.76 957.86 862.46

Competitive Comparison of NeuroMetrix's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, NeuroMetrix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroMetrix's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's Cyclically Adjusted PS Ratio falls into.



NeuroMetrix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeuroMetrix's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.141/129.4194*129.4194
=1.141

Current CPI (Dec. 2023) = 129.4194.

NeuroMetrix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 666.000 99.695 864.574
201406 672.000 100.560 864.859
201409 476.000 100.428 613.412
201412 470.000 99.070 613.983
201503 427.667 99.621 555.589
201506 306.250 100.684 393.655
201509 410.800 100.392 529.582
201512 547.400 99.792 709.916
201603 379.167 100.470 488.418
201606 378.143 101.688 481.266
201609 423.625 101.861 538.236
201612 464.375 101.863 590.001
201703 331.231 102.862 416.749
201706 269.375 103.349 337.326
201709 141.880 104.136 176.328
201712 159.000 104.011 197.841
201803 28.738 105.290 35.324
201806 21.563 106.317 26.249
201809 21.075 106.507 25.609
201812 21.431 105.998 26.166
201903 17.846 107.251 21.535
201906 20.841 108.070 24.958
201909 17.115 108.329 20.447
201912 11.230 108.420 13.405
202003 11.934 108.902 14.182
202006 3.607 108.767 4.292
202009 4.304 109.815 5.072
202012 3.819 109.897 4.497
202103 4.537 111.754 5.254
202106 4.248 114.631 4.796
202109 2.839 115.734 3.175
202112 2.190 117.630 2.410
202203 2.677 121.301 2.856
202206 2.446 125.017 2.532
202209 2.247 125.227 2.322
202212 1.950 125.222 2.015
202303 1.795 127.348 1.824
202306 1.680 128.729 1.689
202309 1.130 129.860 1.126
202312 1.141 129.419 1.141

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


NeuroMetrix  (NAS:NURO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NeuroMetrix's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.44/862.46
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NeuroMetrix was 0.04. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NeuroMetrix Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroMetrix (NeuroMetrix) Business Description

Traded in Other Exchanges
N/A
Address
4B Gill Street, Woburn, MA, USA, 01801
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Executives
Bradley M Fluegel director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins officer: Chief Financial Officer
Topline Capital Management, Llc other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp 10 percent owner 544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin other: See Explanation in Footnotes 544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani director, officer: Chairman, President and CEO C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin officer: Senior VP, Consumer C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van director C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran officer: S. VP and GM, International C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz director CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc officer: Senior Vice President & GM
Walter Christensen officer: Sr. VP, Global Sales C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor director 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C) 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017